Brain Ischemia Market Research Report - Global Forecast till 2027

Brain Ischemia Market Research Report: Information by Condition Type (Focal Brain Ischemia and Global Brain Ischemia), Treatment [Angioplasty, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and others], End User (Hospitals & Clinics, Research & Academic Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2027

ID: MRFR/MED/0915-HCR | February 2021 | Region: Global | 85 pages

Brain Ischemia Market Scenario


Brain Ischemia Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 606.73 million in 2018 and is projected to register a 6.57% CAGR over the forecast period.


Brain ischemia occurs when there is insufficient blood flow to the brain to meet the metabolic demand. This condition leads to poor oxygen supply or cerebral hypoxia and hence leading to the death of the brain tissues or brain ischemia.


Factors such as the increasing burden of ischemic strokes and growth in the geriatric population which is prone to brain ischemia are expected to drive the market growth. According to a survey carried out by the World Health Organization (WHO) in 2019, ischemic stroke is the third most cause of death in the adult population. Moreover, the rising focus of companies for developing drugs for the treatment of brain ischemia is also expected to boost market growth.


However, factors such as the stringent government regulations and limited availability of the treatment options are expected to hamper the market growth. 


Segmentation


The market has been segmented into condition type, treatment, end users, and region.


Based on condition type, the market has been segmented into focal brain ischemia and brain ischemia.


The market, by treatment, has been segmented into angioplasty, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and others.


The market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The brain ischemia market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European brain ischemia market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 


The brain ischemia market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The Middle East & Africa brain ischemia market is segmented into the Middle East and Africa.


Key Players


Taxus Cardium (US), Edwards Lifesciences Corporation (US), Boston Scientific Corporation (US), Merck KGaA (Germany), Medtronic (Ireland), Cook Medical (US), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Abbott (US), Becton, Dickinson and Company (US), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK) are some of the key players operating in the market.


Regional Market Summary


Brain Ischemia Market Share (%), by Region, 2018


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the brain ischemia market owing to the rising prevalence of brain ischemia and presence of a well-established healthcare system. According to the Centers for Disease Control and Prevention (CDC), as of September 2017, 87% of all strokes in the US were ischemic strokes.


Europe is expected to hold the second-largest position in the brain ischemia market owing to the presence of well-developed healthcare infrastructure, availability of funds for research, and increasing healthcare expenditure.


Asia-Pacific is expected to be the fastest-growing regional market owing to the presence of emerging economies of China, India, and South Korea and large patient pool suffering from brain ischemia.


The brain ischemia market in the Middle East & Africa is expected to slowly grow owing to the presence of developing countries such as Egypt, Saudi Arabia, surging healthcare costs, and the growth of the healthcare industry.


Brain Ischemia Market, by Condition Type



  • Focal Brain Ischemia

  • Global Brain Ischemia


Brain Ischemia Market, by Treatment



  • Angioplasty

  • Beta-Blockers

  • Angiotensin-Converting Enzyme (ACE) Inhibitors

  • Others


Brain Ischemia Market, by End User



  • Hospitals and Clinics

  • Research and Academic Institutes

  • Others


Brain Ischemia Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Biotechnology companies

  • Research institutes

  • Medical device companies

  • Pharmaceutical companies

  • Hospitals and clinics

  • Ambulatory surgical centers

  • Academic institutes

  • Government organizations


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the brain ischemia market owing to the rising prevalence of brain ischemia and presence of a well-established healthcare system. According to the Centers for Disease Control and Prevention (CDC), as of September 2017, 87% of all strokes in the US were ischemic strokes.


Europe is expected to hold the second-largest position in the brain ischemia market owing to the presence of well-developed healthcare infrastructure, availability of funds for research, and increasing healthcare expenditure.


Asia-Pacific is expected to be the fastest-growing regional market owing to the presence of emerging economies of China, India, and South Korea and large patient pool suffering from brain ischemia.


The brain ischemia market in the Middle East & Africa is expected to slowly grow owing to the presence of developing countries such as Egypt, Saudi Arabia, surging healthcare costs, and the growth of the healthcare industry.


Global Brain Ischemia Market, by Condition Type



  • Focal Brain Ischemia

  • Global Brain Ischemia


Global Brain Ischemia Market, by Treatment



  • Angioplasty

  • Beta-Blockers

  • Angiotensin-Converting Enzyme (ACE) Inhibitors

  • Others


Global Brain Ischemia Market, by End User



  • Hospitals and Clinics

  • Research and Academic Institutes

  • Others


Global Brain Ischemia Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Biotechnology companies

  • Research institutes

  • Medical device companies

  • Pharmaceutical companies

  • Hospitals and clinics

  • Ambulatory surgical centers

  • Academic institutes

  • Government organizations



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 606.73 Million (2018)
  CAGR   6.57% (2019-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Information by Condition Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Taxus Cardium (US), Edwards Lifesciences Corporation (US), Boston Scientific Corporation (US), Merck KGaA (Germany), Medtronic (Ireland), Cook Medical (US), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Abbott (US), Becton, Dickinson and Company (US), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK)
  Key Market Opportunities

  • Factors such as the increasing burden of ischemic strokes and growth in the geriatric population which is prone to brain ischemia are expected to drive the market growth.\r\n
  • According to a survey carried out by the World Health Organization (WHO) in 2019
  •   Key Market Drivers   The rising focus of companies for developing drugs for the treatment of brain ischemia is also expected to boost market growth.


    Speak to Analyst Ask for Customization

    Table of Contents

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis


    6. GLOBAL BRAIN ISCHEMIA MARKET, BY CONDITION TYPE

    6.1. Overview

    6.2. Focal Brain Ischemia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Global Brain Ischemia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL BRAIN ISCHEMIA MARKET, BY TREATMENT

    7.1. Overview

    7.2. Angioplasty

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Beta Blockers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Angiotensin-Converting Enzyme (ACE) Inhibitors

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL BRAIN ISCHEMIA MARKET, BY END USER

    8.1. Overview

    8.2. Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3. Research and Academic Institutes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9. GLOBAL BRAIN ISCHEMIA MARKET, BY REGION

    9.1. Overview

    9.2. Americas

    9.2.1. North America

    9.2.1.1. US

    9.2.1.2. Canada

    9.2.2. Latin America

    9.3. Europe

    9.3.1. Western Europe

    9.3.1.1. Germany

    9.3.1.2. France

    9.3.1.3. Italy

    9.3.1.4. Spain

    9.3.1.5. UK

    9.3.1.6. Rest of Western Europe

    9.3.2. Eastern Europe

    9.4. Asia-Pacific

    9.4.1. Japan

    9.4.2. China

    9.4.3. India

    9.4.4. Australia

    9.4.5. South Korea

    9.4.6. Rest of Asia-Pacific

    9.5. Middle East & Africa

    9.5.1. Middle East

    9.5.2. Africa

    10. COMPANY LANDSCAPE

    10.1. Overview

    10.2. Competitive Analysis

    10.3. Market Share Analysis

    10.4. Major Growth Strategy in the Global Brain Ischemia Market

    10.5. Competitive Benchmarking

    10.6. Leading Players in terms of Number of Developments in the Global Brain Ischemia Market

    10.7. Key Developments and Growth Strategies

    10.7.1. New Product Launch/Service Deployment

    10.7.2. Mergers and Acquisitions

    10.7.3. Joint Ventures

    10.8. Major Players Financial Matrix & Market Ratio

    10.8.1. Sales & Operating Income 2020

    10.8.2. Major Players R&D Expenditure 2020

    10.9. Major Players Capital Market Ratio

    11. COMPANY PROFILES

    11.1. Taxus Cardium

    11.1.1. Company Overview

    11.1.2. Product Overview

    11.1.3. Financial Overview

    11.1.4. Key Developments

    11.1.5. SWOT Analysis

    11.1.6. Key Strategies

    11.2. Edwards Lifesciences Corporation

    11.2.1. Company Overview

    11.2.2. Product Overview

    11.2.3. Financial Overview

    11.2.4. Key Developments

    11.2.5. SWOT Analysis

    11.2.6. Key Strategies

    11.3. Boston Scientific Corporation

    11.3.1. Company Overview

    11.3.2. Product Overview

    11.3.3. Financial Overview

    11.3.4. Key Developments

    11.3.5. SWOT Analysis

    11.3.6. Key Strategies

    11.4. Merck KGaA

    11.4.1. Company Overview

    11.4.2. Product Overview

    11.4.3. Financial Overview

    11.4.4. Key Developments

    11.4.5. SWOT Analysis

    11.4.6. Key Strategies

    11.5. Medtronic

    11.5.1. Company Overview

    11.5.2. Product Overview

    11.5.3. Financial Overview

    11.5.4. Key Developments

    11.5.5. SWOT Analysis

    11.5.6. Key Strategies

    11.6. Cook Medical

    11.6.1. Company Overview

    11.6.2. Product Overview

    11.6.3. Financial Overview

    11.6.4. Key Developments

    11.6.5. SWOT Analysis

    11.6.6. Key Strategies

    11.7. Novartis AG

    11.7.1. Company Overview

    11.7.2. Product Overview

    11.7.3. Financial Overview

    11.7.4. Key Developments

    11.7.5. SWOT Analysis

    11.7.6. Key Strategies

    11.8. Boehringer Ingelheim International GmbH

    11.8.1. Company Overview

    11.8.2. Product Overview

    11.8.3. Financial Overview

    11.8.4. Key Developments

    11.8.5. SWOT Analysis

    11.8.6. Key Strategies

    11.9. Abbott

    11.9.1. Company Overview

    11.9.2. Product Overview

    11.9.3. Financial Overview

    11.9.4. Key Developments

    11.9.5. SWOT Analysis

    11.9.6. Key Strategies

    11.10. Becton, Dickinson and Company

    11.10.1. Company Overview

    11.10.2. Product Overview

    11.10.3. Financial Overview

    11.10.4. Key Developments

    11.10.5. SWOT Analysis

    11.10.6. Key Strategies

    11.11. Johnson & Johnson Services, Inc.

    11.11.1. Company Overview

    11.11.2. Product Overview

    11.11.3. Financial Overview

    11.11.4. Key Developments

    11.11.5. SWOT Analysis

    11.11.6. Key Strategies

    11.12. Bayer AG

    11.12.1. Company Overview

    11.12.2. Product Overview

    11.12.3. Financial Overview

    11.12.4. Key Developments

    11.12.5. SWOT Analysis

    11.12.6. Key Strategies

    11.13. AstraZeneca

    11.13.1. Company Overview

    11.13.2. Product Overview

    11.13.3. Financial Overview

    11.13.4. Key Developments

    11.13.5. SWOT Analysis

    11.13.6. Key Strategies

    11.14. Others

    12. APPENDIX

    12.1. References

    12.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL BRAIN ISCHEMIA MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL BRAIN ISCHEMIA MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL BRAIN ISCHEMIA MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 7 NORTH AMERICA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 8 NORTH AMERICA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 10 US: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 11 US: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 12 US: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 13 CANADA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 14 CANADA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 15 CANADA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 16 LATIN AMERICA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 17 LATIN AMERICA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 18 LATIN AMERICA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 19 EUROPE: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 20 EUROPE: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 21 EUROPE: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 22 WESTERN EUROPE: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 23 WESTERN EUROPE: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 24 WESTERN EUROPE: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 25 EASTERN EUROPE: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 26 EASTERN EUROPE: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 27 EASTERN EUROPE: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 28 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 29 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 30 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 31 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET, BY CONDITION TYPE, 2020-2027 (USD MILLION)

    TABLE 32 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 33 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET, BY END USER, 2020-2027 (USD MILLION)


    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BRAIN ISCHEMIA MARKET

    FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BRAIN ISCHEMIA MARKET

    FIGURE 4 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY CONDITION TYPE, 2020 (%)

    FIGURE 5 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY TREATMENT, 2020 (%)

    FIGURE 6 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY END USER, 2020 (%)

    FIGURE 7 GLOBAL BRAIN ISCHEMIA MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 7 AMERICAS: BRAIN ISCHEMIA MARKET SHARE BY REGION, 2020 (%)

    FIGURE 8 NORTH AMERICA: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 9 EUROPE: BRAIN ISCHEMIA MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 10 WESTERN EUROPE: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 11 ASIA-PACIFIC: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 12 MIDDLE EAST & AFRICA: BRAIN ISCHEMIA MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 13 GLOBAL BRAIN ISCHEMIA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 14 TAXUS CARDIUM.: KEY FINANCIALS

    FIGURE 15 TAXUS CARDIUM: SEGMENTAL REVENUE

    FIGURE 16 TAXUS CARDIUM: REGIONAL REVENUE

    FIGURE 17 EDWARDS LIFESCIENCES CORPORATION: KEY FINANCIALS

    FIGURE 18 EDWARDS LIFESCIENCES CORPORATION: SEGMENTAL REVENUE

    FIGURE 19 EDWARDS LIFESCIENCES CORPORATION: REGIONAL REVENUE

    FIGURE 20 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS

    FIGURE 21 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE

    FIGURE 22 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE

    FIGURE 23 MERCK KGAA: KEY FINANCIALS

    FIGURE 24 MERCK KGAA: SEGMENTAL REVENUE

    FIGURE 25 MERCK KGAA: REGIONAL REVENUE

    FIGURE 26 MEDTRONIC: KEY FINANCIALS

    FIGURE 27 MEDTRONIC: SEGMENTAL REVENUE

    FIGURE 28 MEDTRONIC: REGIONAL REVENUE

    FIGURE 29 COOK MEDICAL: KEY FINANCIALS

    FIGURE 30 COOK MEDICAL: SEGMENTAL REVENUE

    FIGURE 31 COOK MEDICAL: REGIONAL REVENUE

    FIGURE 32 NOVARTIS AG: KEY FINANCIALS

    FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

    FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

    FIGURE 35 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY FINANCIALS

    FIGURE 36 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SEGMENTAL REVENUE

    FIGURE 37 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REGIONAL REVENUE

    FIGURE 38 ABBOTT: KEY FINANCIALS

    FIGURE 39 ABBOTT: SEGMENTAL REVENUE

    FIGURE 40 ABBOTT: REGIONAL REVENUE

    FIGURE 41 BECTON, DICKINSON AND COMPANY: KEY FINANCIALS

    FIGURE 42 BECTON, DICKINSON AND COMPANY: SEGMENTAL REVENUE

    FIGURE 43 BECTON, DICKINSON AND COMPANY: REGIONAL REVENUE

    FIGURE 44 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

    FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

    FIGURE 46 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

    FIGURE 47 BAYER AG: KEY FINANCIALS

    FIGURE 48 BAYER AG: SEGMENTAL REVENUE

    FIGURE 49 BAYER AG: REGIONAL REVENUE

    FIGURE 50 ASTRAZENECA: KEY FINANCIALS

    FIGURE 51 ASTRAZENECA: SEGMENTAL REVENUE

    FIGURE 52 ASTRAZENECA: REGIONAL REVENUE